ArticleBlood advances2022
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.
Open access · goldAbstract read
In one paragraph
Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 52 citations in OpenAlex.
- Trial
- Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia.Blood advances · 2026Article
- Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.Internal medicine journal · 2026Article
- Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic Strategies.International journal of molecular sciences · 2026Review
- Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives.European journal of haematology · 2026Review
- Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective.Blood advances · 2026Review
- Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia.HemaSphere · 2025Article
- Management of Relapsed and/or Refractory Chronic Lymphocytic Leukemia.Hematology/oncology clinics of North America · 2025Review
- Developing MRD as an early endpoint for accelerated approval in CLL.Seminars in hematology · 2025Review
- Article
- Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.Leukemia & lymphoma · 2025Review
- Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL.Blood advances · 2025Article
- Review
- Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center.Advances in hematology · 2025Article
- Risk-stratification in frontline CLL therapy: standard of care.Hematology. American Society of Hematology. Education Program · 2024Review
- Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed.Cancers · 2024Review
- Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia.Hematology reports · 2024Review
- Frontline Therapy of CLL-Changing Treatment Paradigms.Current hematologic malignancy reports · 2024Review
- Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.Blood advances · 2024Article
- Update on the management of relapsed/refractory chronic lymphocytic leukemia.Blood cancer journal · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 20 institutions in 5 countries.
Meghan C ThompsonDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.ORCID 0000-0003-1462-4802
Rosemary A HarrupRoyal Hobart Hospital, Tasmania, Australia.
Catherine C CoombsUniversity of North Carolina, Chapel Hill, NC.
Lindsey E RoekerDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.ORCID 0000-0002-3806-059X
Jeffrey J PuUniversity of Arizona Cancer Center, Tuscon, AZ.ORCID 0000-0001-7498-3159
Michael Y ChoiUniversity of California, San Diego, San Diego, CA.
Paul M BarrWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.ORCID 0000-0002-9733-401X
John N AllanWeill Cornell Medicine, New York, NY.ORCID 0000-0002-2088-0899
Martin ŠimkovičUniversity Hospital Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.ORCID 0000-0003-0331-5334
Lori LeslieHackensack University Medical Center, Hackensack, NJ.
Joanna RhodesNorthwell Health Cancer Institute, Lake Success, NY.
Elise A ChongUniversity of Pennsylvania, Philadelphia, PA.ORCID 0000-0001-8895-1625
Manali KamdarUniversity of Colorado Cancer Center, Denver, CO.
Alan SkarbnikNovant Health, Charlotte, NC.
Frederick LansiganDartmouth-Hitchcock Medical Center, Lebanon, NH.
Brittany McCallDartmouth-Hitchcock Medical Center, Lebanon, NH.
Khalid SajaColchester General Hospital, East Suffolk, and North Essex NHS Foundation Trust, Essex, United Kingdom.ORCID 0000-0002-0271-8732
Martin J S DyerThe Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, United Kingdom.ORCID 0000-0002-5033-2236
Harriet S WalterThe Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, United Kingdom.ORCID 0000-0003-2618-711X
Marcus LefebureRoche Products Ltd, Welwyn Garden City, United Kingdom.
Maria Thadani-MuleroRoche Products Ltd, Welwyn Garden City, United Kingdom.
Michelle BoyerRoche Products Ltd, Welwyn Garden City, United Kingdom.
Juliana BiondoGenentech, Inc., South San Francisco, CA.
Kavita SailAbbVie, Inc., North Chicago, IL.
Beenish S ManzoorAbbVie, Inc., North Chicago, IL.
Richard FurmanWeill Cornell Medicine, New York, NY.
Kurt S BantilanDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
Andre GoyHackensack University Medical Center, Hackensack, NJ.ORCID 0000-0001-5125-6522
Tatyana FeldmanHackensack University Medical Center, Hackensack, NJ.
Dominic LabellaRiverside Regional Medical Center, Newport News, VA.ORCID 0000-0003-1713-9538
Stephen J SchusterUniversity of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-3376-8978
Jae ParkDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
Lia PalombaDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
Andrew ZelenetzDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.ORCID 0000-0003-1403-6883
Toby A EyreOxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.ORCID 0000-0002-6631-9749
Arnon P KaterAmsterdam University Medical Centers, Amsterdam, The Netherlands; and.ORCID 0000-0003-3190-1891
John F SeymourRoyal Melbourne Hospital, Peter McCallum Cancer Centre, and University of Melbourne, Melbourne, Australia.ORCID 0000-0003-2188-6835
Anthony R MatoDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
Memorial Sloan Kettering Cancer Center · USHackensack University Medical Center · USRoche (United Kingdom) · GBAbbVie (United States) · USCornell University · USDartmouth–Hitchcock Medical Center · USUniversity of Leicester · GBUniversity of Pennsylvania · USAmsterdam University Medical Centers · NLCharles University · CZEast Suffolk and North Essex NHS Foundation Trust · GBNorthwell Health · USNovant Health · USOxford University Hospitals NHS Trust · GBRiverside Regional Medical Center · USRoyal Hobart Hospital · AUThe Royal Melbourne Hospital · AUUniversity of Arizona · USUniversity of California San Diego · USUniversity of Colorado Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Lymphocytic, Chronic, B-CellBridged Bicyclo Compounds, HeterocyclicHumansRetreatmentSulfonamidesBridged Bicyclo Compounds, HeterocyclicSulfonamidesvenetoclax
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.